

**AMENDMENTS (CLEAN VERSION)**

**IN THE CLAIMS:**

**Please cancel Claim 2 without prejudice to this or related cases.**

**Please rewrite Claims 1, 7, 11, and 17 as follows:**

A<sup>1</sup> 1. (amended) A purified peptide fragment with selective binding to tumor-derived endothelial cells, wherein the peptide fragment possesses a charge motif of positive- positive- neutral hydrophobic (++O), wherein the peptide fragment is not greater than fifty amino acid residues in length.

A<sup>2</sup> 7. (amended) A composition useful for targeting tumor-derived endothelial cells, said composition comprising a peptide selected from the group consisting essentially of SEQ ID NO 1 Cys-Gly-Gly-Arg-His-Ser-Gly-Gly-Cys; SEQ ID NO 2 Cys-Gly-Gly-Arg-Lys-Leu-Gly-Gly-Cys; SEQ ID NO 3 Cys-Gly-Gly-Arg-Arg-Leu-Gly-Gly-Cys; SEQ ID NO 4 Cys-Gly-Gly-Arg-Arg-Ser-Arg-Gly-Gly-Cys; and SEQ ID NO 5 Cys-Leu-Leu-Arg-Arg-Ser-Arg-Leu-Leu-Cys.

A<sup>3</sup> 11. (amended) The composition of Claim 8, wherein said therapeutic agent includes at least one agent selected from the group consisting essentially of anticellular agents, chemotherapeutic agents, radioisotopes, and cytotoxins.

A<sup>4</sup> 17. (amended) The composition of Claim 7, wherein said peptide is linked to a diagnostic agent that is detectable upon imaging.